Mission Bio, Inc. announced that it has been awarded a grant from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) program to develop more advanced methods of quantifying molecular minimal residual disease (MRD) in acute myeloid leukemia (AML). In partnership with Dr. Jerry Radich of Fred Hutchinson Cancer Research Center, the project will leverage Mission Bio's Tapestri Platform to enable more accurate prediction of patient outcomes and empower the development of more impactful treatments aimed at residual disease.
The Tapestri Platform is the only single-cell targeted DNA solution available to effectively detect rare cancer subclones and co-occurring cancer mutations, addressing the shortcomings of traditional methods by providing a more accurate lens into the cells that drive disease progression and subsequent relapse.
The news comes on the heels of a strong push from Mission Bio to support biopharmaceutical customers -- partners like LabCorp and Onconova Therapeutics leverage the Tapestri Platform to fill their need for faster, more precise clinical trials.
